Friday, 20 Sep 2019

You are here

Weight Loss Improves Psoriasis

Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition. (Citation source: http://buff.ly/2j8zHWo),

They examined long-term outcomes of weight loss in 56 obese patients with a mean PASI score of 5.4 and a body mass index of 34.4 kg/m2. Patients were randomized to a low-energy diet (LED) group or a control group given general advice to eat healthy foods.

The diet consisted of 8 weeks of a low-energy liquid (fortified drinks and soups) diet (800-1,000 kcal) followed by 8 weeks in which regular foods were reintroduced at 1,200 kcal/day. Patients underwent a 64-week weight-loss program consisting of an initial 16-week randomized phase with an LED for 8 weeks and 8 weeks of normal food intake combined with 2 LED products/day, followed by a 48-week period of weight maintenance with the latter diet. After the randomization phase, the control group received the same 8 + 8-week LED intervention, and all patients were then followed for 48 weeks while on the weight-loss maintenance diet.

After the initial 16-wk LED-only period, the mean weight loss was −15.0 kg along with a decrease in PASI (-2.3) and DLQI (−2.3). At week 64, the mean weight loss compared with baseline was −10.1 kg and the PASI and DLQI reductions were maintained at −2.9 and −1.9, respectively.

Long-term weight loss in patients with psoriasis has long-lasting positive effects on the severity of psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.